INHX - Inhibitex Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INHX - Inhibitex Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: John McCarthy	12/13/2010 5:41:54 PM
	of 3

UPDATE 1-Inhibitex shingles drug fails in mid-stage trial Dec 13 (Reuters) - Biotechnology company Inhibitex Inc's (INHX.O) experimental drug to treat shingles failed to meet the main goal of a mid-stage trial, sending its shares down 13 percent. There were "numerically favorable" differences between patients treated with the drug, FV-100, and valacyclovir -- a commonly used antiviral drug for shingles -- but the differences were not statistically significant, Inhibitex said. The main goal of the trial was to show reduction in the severity and duration of shingles-associated acute pain over the first 30 days post-infection. Patients who received 200 mg or 400 mg FV-100 experienced 3 percent and 7 percent relative treatment differences compared to patients treated with valacyclovir, the company said. Inhibitex shares, which have risen 46 percent since the company reported third-quarter results in November, were down 39 cents at $2.50 in extended trade on Monday. (Reporting by Anand Basu in Bangalore; Editing by Vinu Pilakkott) StocksRegulatory NewsGlobal MarketsHealthcare reuters.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext